Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder

Australian and New Zealand Journal of Psychiatry

Volumn 38, Issue 8, 2004, Pages 592-601

  Donnelly, Marie ^b   Haby, Michelle M ^a   Carter, Rob ^c   Andrews, Gavin ^d   Vos, Theo ^a  

^a Public Health   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Attention deficit hyperactivity disorder; Cost effectiveness; Dexamphetamine meta analysis; Methylphenidate

Indexed keywords

ATTENTA; DEXAMPHETAMINE; METHYLPHENIDATE; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CHILD; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GOVERNMENT; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; MENTAL HEALTH; META ANALYSIS; PATIENT COMPLIANCE; RESOURCE ALLOCATION; SIMULATION;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUSTRALIA; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DEXTROAMPHETAMINE; HUMANS; MENTAL HEALTH SERVICES; METHYLPHENIDATE; MONTE CARLO METHOD; PATIENT COMPLIANCE;

EID: 4444262411     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2004.01422.x     Document Type: Article

References (51)

1. Mathers CD, Vos T, Stevenson C. The burden of disease and injury in Australia. Canberra: Australian Institute of Health and Welfare, 1999.
2. Elia J. Abrosini PJ, Rappaport JL. Treatment of attention-deficit hyperactivity disorder. New England Journal of Medicine 1999: 340: 780-788.
3. Miller A, Lee S, Raina P, Klassen A, Zupancic J, Olsen L. A review of therapies for attention-deficit/hyperactivity disorder. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1999.
4. Sawyer MM, Arney FM, Baghurst PA et al. The mental health of young people in Australia. Canberra: Mental Health and Special Programs Branch Commonwealth Department of Health and Aged Care, 2000.
5. Landgraf JM, Abetz L, Ware JE. Child Health Questionnaire (CHQ): a user's manual. Boston: The Health Institute, New England Medical Centre, 1996.
6. Pliszka SR, Greenhill LL, Crimson ML et al. The Texas children's medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part II: tactics, Journal of the American Academy of Child and Adolescent Psychiatry 2000; 39:920-927.
7. The MTA Co-operative Group. A 14-month randomised clinical control trial of treatment strategies for ADHD. Archives of General Psychiatry 1999; 56:1073-1086.
8. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of attention-deficit/hyperactivity disorder: evidence report/technology assessment no. 11. Rockville, MD: Agency for Health Care Policy and Research, 1999.
9. Schachter H, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention deficit disorder in children and adolescents? A meta-analysis. Canadian Medical Association Journal 2001; 165:1475-1488.
10. DuPaul G, Eckert TL. The effects of school-based interventions for attention deficit hyperactivity disorder: a meta-analysis. School Psychology Review 1997; 26:5-27.
11. Gaub M, Carlson C. Gender differences in ADHD: a meta-analysis and critical review. Journal of the American Academy of Child and Adolescent Psychiatry 1997: 36:1036-1045.
12. Klassen A. Miller A, Raina P, Lee SK, Olsen L. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Canadian Journal of Psychiatry 1999; 44:1007-1016.
13. Jadad AR, Booker L, Gauld M et al. The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and meta-analyses. Canadian Journal of Psychiatry 1999; 44:1025-1035.
14. Egger M, Smith G, Altman D. Systematic reviews in health Care: meta-analysis in context, 2nd edn. London: BMJ Books 2001.
15. Elbourne D, Altman D, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology 2002; 31:140-149.
16. Dunlap WP, Cortina JM, Vaslow JB, Burke MJ. Meta-analysis of experiments with matched groups or repeated measures designs. Psychological Methods 1996; 1: 170-177.
17. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith G, Altman D, eds. Systematic reviews in health care: meta-analysis in context. 2nd edn. London: BMJ Publishing Group 2001, 285-312.
18. Elia J, Welsh PA, Gullotta CS, Rapoport JL. Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys. Journal of Child Psychology and Psychiatry 1993; 34:785-804.
19. James RS, Sharp WS, Bastain TM et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 2001; 40:1268-1276.
20. Amery B, Minichiello MD, Brown GL. Aggression in hyperactive boys: response to d-amphetamine. Journal of the American Academy of Child and Adolescent Psychiatry 1984; 23:291-294.
21. Zametkin A, Rapoport J, Murphy DL, Linnoila M, Ismond D. Treatment of hyperactive children with monoamine oxidase inhibitors. Archives of General Psychiatry 1985; 42:962-966.
22. Brown RT, Borden KA, Wynne ME, Spunt AL, Clingerman SR. Compliance with pharmacological and cognitive treatments for attention deficit disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1987; 26:521-526.
23. DuPaul GJ, Rapport MD. Does methylphenidate normalise the classroom performance of children with attention deficit disorder? Journal of the American Academy of Child and Adolescent Psychiatry 1993; 32:190-198.
24. Fitzpatrick PA, Klorman R, Brumaghim JT, Borgstedt AD. Effects of sustained-release and standard preparations of methylphenidate on attention-deficit disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1992; 31:226-243.
25. McBride MC. An individual double-blind crossover trial for assessing methylphenidate response in children with attention deficit disorder. Pediatric Pharmacology and Therapeutics 1988; 113:137-145.
26. Rapport MD, DuPaul GJ, Kelly KL. Attention deficit hyperactivity disorder and methylphenidate: the relationship between gross body weight and drug response in children. Psychopharmacology Bulletin 1989; 25:285-290.
27. Schachar R, Tannock R, Cunningham C, Corkum PV. Behavioural, situational, and temporal effects of treatment of ADHD with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry 1997; 36:754-763.
28. Stein MT, Blondis TA, Schnitzler E et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 1996; 98:748-756.
29. Rapport MD, Jones JT, DuPaul GJ et al. Attention deficit disorder and methylphenidate: group and single-subject analysis of dose effects on attention in clinic and classroom settings. Journal of Clinical Child Psychology 1987; 16:329-338.
30. Wolraich ML, Greenhill LL, Pelham WE et al. Randomised, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108:883-892.
31. Zeiner P, Bryhn G, Bjercke C, Truyen K, Strand G. Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Acta Paediatrica 1999; 88:298-303.
32. Firestone P, Crowe D, Goodman JT, McGrath P. Vicissitudes of follow-up studies: differential effects of parent training and stimulant medication with hyperactives. American Journal of Orthopsychiatry 1986; 56:184-194.
33. Brown RT, Wynne ME, Borden KA, Clingerman SRRG, Spunt AL. Methylphenidate and cognitive therapy in children with attention deficit disorder: a double-blind trial. Developmental and Behavioural Pediatrics 1986; 7:163-170.
34. Smith BH, Pelham WE, Evans SW et al. Dosage effects of methylphenidate on the social behaviour of adolescents diagnosed with attention-deficit hyperactivity disorder. Experimental and Clinical Psychopharmacology 1998; 6:187-204.
35. Carlson C, Pelham WE, Milich R, Dixon J, Single and combined effects of methylphenidate and behaviour therapy on the classroom performance of children with attention-deficit hyperactivity disorder. Journal of Abnormal Child Psychology 1992; 20:213-232.
36. Stouthard M, Essink-Bot M, Bonsel G et al. Disability, weights for diseases in the Netherlands. Rotterdam: Department of Public Health. Erasmus University, 1997.
37. Haby M, Carter R, Mihalopoulos C, Magnus A, Andrews G, Vos T. Assessing Cost-Effectiveness (ACE) - Mental Health: introduction to the study and methods. Australian and New Zealand Journal of Psychiatry, 2004; 38:569-579.
38. Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 2001; 40:922-928.
39. Pharmacy Direct. Pharmacy direct: medicine by mail. 2002 (Available at: http://www.pharmacydirect. com.au Accessed 11 September 2002.)
40. Arrow Pharmaceuticals. Private prescription product range. 2002 (Available at: http://www.arrowpharma.com/about.cfm Accessed 10 September 2002).
41. Caswell A ed. MIMS. Sydney, NSW: MediMedia Australia, 2001.
42. Kauffman RE, Smith-Wright D, Reese CA, Simpson R, Jones F. Medication compliance in hyperactive children. Pediatric Pharmacology 1981; 1:123-237.
43. Gillberg C, Melander H, von Knorring A et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomised, double-blind, placebo-controlled trial. Archives of General Psychiatry, 1997; 54:857-864.
44. Fine S, Worling D. Issues in medication adherence for children and adolescents with attention-deficit hyperactivity disorder. British Columbia Medical Journal 2001; 43:277-281.
45. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 1033-1044.
46. Harris A. Economic evaluation and the reimbursement of pharmaceuticals in Australia. Melbourne: Centre for Health Program Evaluation, 1994.
47. Zupancic J, Miller A, Raina P, Lee PP, Klassen A, Olsen L. Economic evaluation of pharmaceutical and psychological/ behavioural therapies for attention-deficit/hyperactivity disorder. Ottowa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1999.
48. Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD. implications for research, practice, and DSM-V. Journal of the American Academy of Child and Adolescent Psychiatry, 1997; 36:1065-1079.
49. National Institute of Health. Diagnosis and treatment of attention deficit hyperactivity disorder. NIH Consensus Statement online. Bethesda, ML: National Institute of Health, 1998. (Available at: http://Odp Od Nih Gov/Consensus/Cons/110/110-Statement Htm Accessed 27 February 2002.)
50. Klein RG, Abikoff HB. Behaviour therapy and methylphenidate in the treatment of children with ADHD. Journal of Attention Disorders 1997; 2:89-114.
51. Pelham WE, Fabiano GA. Behaviour modification. Child and Adolescent Psychiatric Clinics of North America 2001; 9:671-688.